Shares of Moderna and BioNTech have experienced a significant surge, with Moderna's stock price climbing over 11% on Tuesday and closing with a 13.12% increase. The uptick in Moderna's stock can be attributed to the optimistic outlook provided by CEO Stéphane Bancel. In a letter to shareholders, Bancel projected sales growth for the company in 2025, coinciding with the expected launch of their RSV vaccine. Additionally, an Oppenheimer upgrade and a positive analyst report on Moderna's drug pipeline, which is anticipated to introduce five new products by 2026, further bolstered investor confidence. Moderna also reported that their product sales for 2023 modestly surpassed analyst estimates and achieved a larger share of the U.S. market for Covid-19 vaccines.
Moderna's 2023 prelim COVID vaccine sales meet target https://t.co/tQ01NdmPYi https://t.co/mLWWpXVJAK
Moderna’s product sales for 2023 modestly beat analyst estimates as it eked out a bigger US market share for Covid shots https://t.co/eXQcfibVbc
Is Moderna ready to move beyond the COVID vaccine? A new analyst report suggests Moderna’s drug pipeline is underrated and it could have five new products by 2026. https://t.co/6qXSAifsHD
Moderna jumps on Oppenheimer upgrade, 2025 sales growth goal https://t.co/zjwfEZXmhx 🔼 $MRNA +13.12% https://t.co/N37iVfI1q3
⚠️ MODERNA SURGES AFTER CEO SAYS SALES GROWTH EXPECTED IN 2025 Moderna shares rose more than 11% on Tuesday after the vaccine maker's CEO Stéphane Bancel said in a shareholder letter that the company expects its sales to grow in 2025. "With the expected launch of our RSV…
Moderna and BioNTech shares are surging. You know what that means 🫤.